bioMerieux gets busy, with its sights set on more products, bigger markets in the next millennium
This article was originally published in Clinica
It has been a busy year for bioMerieux. The French company increased its research and development spending to cope with a number of new products currently in the pipeline. It opened five subsidiaries or liaison offices in South America and Asia and it also extended the range of tests for its automated EIA analyser, the Vidas system. bioMerieux says there are 10,000 Vidas units installed worldwide.
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.